Liver Cancer Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Eli Lilly, Merck, Genetech, GlaxoSmithKline, Bristol-Myers Squibb

The Key Liver Cancer Companies in the market include - Eli Lilly, Merck, Genetech, GlaxoSmithKline, Bristol-Myers Squibb, and others.

DelveInsight's "Liver Cancer Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Liver Cancer, historical and forecasted epidemiology as well as the Liver Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Liver Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Liver Cancer Market Forecast [https://www.delveinsight.com/sample-request/liver-cancer-market?utm_source=abewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Liver Cancer Market Report:

*
The Liver Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
In November 2025, Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology firm specializing in therapies for primary and metastatic liver cancers, announced that it has issued equity awards-previously approved by its Compensation Committee as significant incentives to six new employees who joined the company in September or October 2025.

*
Based on data from the Surveillance, Epidemiology, and End Results (SEER) program, the United States reported a liver cancer and intrahepatic bile duct cancer incidence of 9.0 per 100,000, translating to approximately 42,230 new cases in 2021. The mortality rate was 6.6 per 100,000 per year, with a 5-year survival rate of 20.3%. By stage at diagnosis, cases were distributed as Localized (45%), Regional (26%), Distant (18%), and Unknown (11%).

*
Key Liver Cancer Companies: Eli Lilly, Merck, Genetech, GlaxoSmithKline, Bristol-Myers Squibb, and others

*
Key Liver Cancer Therapies: CYRAMZA (ramucirumabis), KEYTRUDA (pembrolizumab), TECENTRIQ (atezolizumab), JEMPERLI (dostarlimab), OPDIVO (nivolumab), YERVOY (ipilimumab), and others

*
The Liver Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Liver Cancer pipeline products will significantly revolutionize the Liver Cancer market dynamics.

Introduction: The Growing Burden of Liver Cancer

Liver Cancer poses a significant and escalating global health challenge, with a growing burden that demands attention. According to the World Cancer Research Fund, liver cancer ranks as the sixth most common cancer worldwide, and it is estimated that nearly 840,000 new cases were diagnosed in 2020 alone. The burden is exacerbated by the fact that liver cancer often remains asymptomatic in its early stages, leading to delayed diagnosis and treatment initiation.

Get a Free sample for the Liver Cancer Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/liver-cancer-market [https://www.delveinsight.com/report-store/liver-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Signs, Symptoms, and Risk Factors of Liver Cancer

Recognizing the signs and symptoms of Liver Cancer is crucial for early detection. Common indicators include unexplained weight loss, abdominal pain, jaundice, and a feeling of fullness. As the disease progresses, additional symptoms such as fatigue and easy bruising may manifest. Risk factors for developing Liver Cancer include chronic infection with hepatitis B or C, excessive alcohol consumption, obesity, and non-alcoholic fatty liver disease. Understanding these risk factors is essential for identifying individuals who may be at higher risk and implementing preventive measures.

Diagnosing Liver Cancer: Challenges and Advances

Diagnosing Liver Cancer often involves a combination of imaging studies, blood tests, and sometimes liver biopsy. However, the challenge lies in the fact that symptoms may not become apparent until the disease has reached an advanced stage. Advances in diagnostic technologies, including the use of imaging modalities such as computed tomography (CT) scans and magnetic resonance imaging (MRI), have improved the accuracy and efficiency of detecting liver cancer. Early diagnosis remains pivotal for effective treatment and improved patient outcomes.

Liver Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Liver Cancer Epidemiology Segmentation:

The Liver Cancer market report proffers epidemiological analysis for the study period 2020-2032 in the 7MM segmented into:

*
Total Prevalence of Liver Cancer

*
Prevalent Cases of Liver Cancer by severity

*
Gender-specific Prevalence of Liver Cancer

*
Diagnosed Cases of Episodic and Chronic Liver Cancer

Download the report to understand which factors are driving Liver Cancer epidemiology trends @ Liver Cancer Epidemiology Forecast [https://www.delveinsight.com/sample-request/liver-cancer-market?utm_source=abewswire&utm_medium=pressrelease&utm_campaign=gpr]

Evolving Treatment Outlook for Liver Cancer

The treatment landscape for Liver Cancer has seen significant advancements in recent years. Major treatment options include surgery, localized therapies such as radiofrequency ablation, systemic therapies like chemotherapy, and targeted therapies. The choice of treatment depends on various factors, including the stage of the cancer, the patient's overall health, and the extent of liver damage. Integrative approaches that combine different modalities are often employed to maximize treatment efficacy and minimize side effects.

Market Outlook and Growth Factors in Liver Cancer

The market for Liver Cancer therapies is witnessing a surge in research and development activities, driven by the increasing prevalence of the disease. Growing awareness, improved diagnostic capabilities, and the emergence of novel treatment modalities contribute to the expansion of the Liver Cancer market. Factors such as the rising aging population and the persistent global burden of hepatitis infections are anticipated to fuel market growth. As pharmaceutical companies continue to invest in innovative therapeutic approaches, the outlook for Liver Cancer treatment holds promise, aiming to enhance patient outcomes and overall survival rates.

Liver Cancer Emerging Therapies and Companies

*
CYRAMZA (ramucirumabis): Eli Lilly

*
KEYTRUDA (pembrolizumab): Merck

*
TECENTRIQ (atezolizumab): Genetech

*
JEMPERLI (dostarlimab): GlaxoSmithKline

*
OPDIVO (nivolumab): Bristol-Myers Squibb

*
YERVOY (ipilimumab): Bristol-Myers Squibb

Scope of the Liver Cancer Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Liver Cancer Companies: Eli Lilly, Merck, Genetech, GlaxoSmithKline, Bristol-Myers Squibb, and others

*
Key Liver Cancer Therapies: CYRAMZA (ramucirumabis), KEYTRUDA (pembrolizumab), TECENTRIQ (atezolizumab), JEMPERLI (dostarlimab), OPDIVO (nivolumab), YERVOY (ipilimumab), and others

*
Liver Cancer Therapeutic Assessment: Liver Cancer current marketed and Liver Cancer emerging therapies

*
Liver Cancer Market Dynamics: Liver Cancer market drivers and Liver Cancer market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Liver Cancer Unmet Needs, KOL's views, Analyst's views, Liver Cancer Market Access and Reimbursement

To know more about Liver Cancer companies working in the treatment market, visit @ Liver Cancer Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/liver-cancer-market?utm_source=abewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Liver Cancer Market Report Introduction

2. Executive Summary for Liver Cancer

3. SWOT analysis of Liver Cancer

4. Liver Cancer Patient Share (%) Overview at a Glance

5. Liver Cancer Market Overview at a Glance

6. Liver Cancer Disease Background and Overview

7. Liver Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Liver Cancer

9. Liver Cancer Current Treatment and Medical Practices

10. Liver Cancer Unmet Needs

11. Liver Cancer Emerging Therapies

12. Liver Cancer Market Outlook

13. Country-Wise Liver Cancer Market Analysis (2020-2034)

14. Liver Cancer Market Access and Reimbursement of Therapies

15. Liver Cancer Market Drivers

16. Liver Cancer Market Barriers

17. Liver Cancer Appendix

18. Liver Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=liver-cancer-market-poised-for-significant-growth-from-2024-to-2034-reports-delveinsight-eli-lilly-merck-genetech-glaxosmithkline-bristolmyers-squibb]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.